Predicted protein targets (top 4)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PARP1 | P09874 | 12/20 | 1.00 |
| ▸ | PARP2 | Q9UGN5 | 5/20 | 1.00 |
| ▸ | CYP2D6 | P10635 | 1/20 | 1.00 |
| ▸ | CYP2B6 | P20813 | 1/20 | 1.00 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL571003 | 1.00 | PARP1 (1.00) | PARP1PARP2CYP2D6CYP2B6 | |
| SCHEMBL15662387 | 0.92 | PARP1 (0.85) | PARP1PARP2CYP2D6CYP2B6 | |
| SCHEMBL15662088 | 0.91 | PARP1 (0.83) | PARP1PARP2CYP2D6CYP2B6 | |
| SCHEMBL1881724 | 0.91 | PARP1 (1.00) | PARP1PARP2CYP2D6CYP2B6 | |
| SCHEMBL1860629 | 0.90 | PARP1 (1.00) | PARP1PARP2CYP2D6CYP2B6 | |
| SCHEMBL15662751 | 0.88 | PARP1 (0.79) | PARP1PARP2CYP2D6CYP2B6 | |
| SCHEMBL1865934 | 0.88 | PARP1 (0.79) | PARP1PARP2CYP2D6CYP2B6 | |
| SCHEMBL1876306 | 0.87 | PARP1 (0.77) | PARP1PARP2CYP2D6CYP2B6 | |
| SCHEMBL30417915 | 0.87 | PARP1 (0.77) | PARP1PARP2CYP2D6CYP2B6 | |
| SCHEMBL1874517 | 0.87 | PARP1 (0.77) | PARP1PARP2CYP2D6CYP2B6 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 173 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2026106998-A1 | PROSTATE-SPECIFIC MEMBRANE ANTIGEN (PSMA)-TARGETED POLY(ADP-RIBOSE) POLYMERASE (PARP) INHIBITOR AND RELATED COMPOSITION AND METHOD OF USE | PURDUE RESEARCH FOUNDATION (US) | 2026-05-21 | — | — | WO | claimed |
| EP-4739310-A1 | ECTONUCLEOTIDE PYROPHOSPHATASE/PHOSPHODIESTERASE 1 (ENPP1) INHIBITOR COMBINATIONS AND USES THEREOF | Insilico Medicine IP Limited (HK) | 2026-05-13 | — | — | EP | claimed |
| US-20250381202-A1 | PRODRUG KIT FOR MULTI-PRONGED CHEMOTHERAPY | ZOUNEK ALEX (DE) | 2025-12-18 | — | — | US | claimed |
| CN-120077031-A | Prodrug kit for multitube concurrent chemotherapy | 亚历克斯·祖内克 | 2025-05-30 | — | — | CN | claimed |
| EP-4551565-A1 | PRODRUG KIT FOR MULTI-PRONGED CHEMOTHERAPY | Zounek, Alex (DE) | 2025-05-14 | — | — | EP | claimed |
| WO-2025007955-A1 | ECTONUCLEOTIDE PYROPHOSPHATASE/PHOSPHODIESTERASE 1 (ENPP1) INHIBITOR COMBINATIONS AND USES THEREOF | INSILICO MEDICINE IP LIMITED (CN) | 2025-01-09 | — | — | WO | claimed |
| WO-2024217502-A1 | METHIONINE ADENOSYLTRANSFERASE 2A (MAT2A) INHIBITOR COMBINATIONS AND USES THEREOF | INSILICO MEDICINE IP LIMITED (CN) | 2024-10-24 | — | — | WO | claimed |
| WO-2024137738-A1 | COMBINATIONS OF POLY (ADP-RIBOSE) POLYMERASE (PARP) INHIBITORS AND HETEROAROTINOIDS AND METHODS OF USE AS CANCER TREATMENTS | THE BOARD OF REGENTS OF THE UNIVERSITY OF OKLAHOMA (US) | 2024-06-27 | — | — | WO | claimed |
| WO-2024008833-A1 | PRODRUG KIT FOR MULTI-PRONGED CHEMOTHERAPY | ZOUNEK ALEX (DE) | 2024-01-11 | — | — | WO | claimed |
| US-20230293565-A1 | USE OF WNT/BETA-CATENIN PATHWAY INHIBITORS TO BLOCK REPLICATION OF SARS-COV-2 AND OTHER PATHOGENIC VIRUSES | THE GOVERNORS OF THE UNIVERSITY OF ALBERTA (CA) | 2023-09-21 | — | — | US | claimed |
| CN-116249520-A | Blocking replication of SARS-COV-2 and other pathogenic viruses using WNT/beta-catenin pathway inhibitors | 阿尔伯塔大学理事会 | 2023-06-09 | — | — | CN | claimed |
| EP-4188378-A1 | USE OF WNT/BETA-CATENIN PATHWAY INHIBITORS TO BLOCK REPLICATION OF SARS-COV-2 AND OTHER PATHOGENIC VIRUSES | The Governors of the University of Alberta (CA) | 2023-06-07 | — | — | EP | claimed |
| US-20230123585-A1 | COMPOSITIONS AND METHODS FOR TREATING OR PREVENTING CANCER USING DEUBIQUITINASE INHIBITORS | UNIV CHICAGO (US) | 2023-04-20 | — | — | US | claimed |
| WO-2022020967-A1 | USE OF WNT/BETA-CATENIN PATHWAY INHIBITORS TO BLOCK REPLICATION OF SARS-COV-2 AND OTHER PATHOGENIC VIRUSES | THE GOVERNORS OF THE UNIVERSITY OF ALBERTA (CA) | 2022-02-03 | — | — | WO | claimed |
| EP-4048809-B1 | SYSTEMS AND METHODS FOR PREDICTING THERAPEUTIC SENSITIVITY | TEMPUS AI INC (US) | 2026-05-27 | — | — | EP | disclosed |
| WO-2026106998-A1 | PROSTATE-SPECIFIC MEMBRANE ANTIGEN (PSMA)-TARGETED POLY(ADP-RIBOSE) POLYMERASE (PARP) INHIBITOR AND RELATED COMPOSITION AND METHOD OF USE | PURDUE RESEARCH FOUNDATION (US) | 2026-05-21 | — | — | WO | disclosed |
| CN-122059926-A | Heterocyclic degradation determinants for target protein degradation | C4医药公司 | 2026-05-19 | — | — | CN | disclosed |
| CN-112569233-B | Application of PARP inhibitor PJ34 in preparation of fish rhabdovirus resistant product | 中国水产科学研究院黑龙江水产研究所 | 2022-03-01 | — | — | CN | disclosed |
| WO-2022020967-A1 | USE OF WNT/BETA-CATENIN PATHWAY INHIBITORS TO BLOCK REPLICATION OF SARS-COV-2 AND OTHER PATHOGENIC VIRUSES | THE GOVERNORS OF THE UNIVERSITY OF ALBERTA (CA) | 2022-02-03 | — | — | WO | disclosed |
| EP-3941481-A1 | COMPOSITIONS COMPRISING A PHOSPHORUS DERIVATIVE OF NICOTINAMIDE RIBOSIDE AND METHODS FOR MODULATION OF NICOTINAMIDE ADENINE DINUCLEOTIDE | Metro International Biotech, LLC (US) | 2022-01-26 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20250381202-A1 | PRODRUG KIT FOR MULTI-PRONGED CHEMOTHERAPY | KIT, CTSL, PAICS | PARP1 534/4885PARP2 927/4885CYP2D6 2150/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.